Tianjin University

Jiangsu Hengrui Medicine Company Ltd.

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Nantong Licheng Biological Engineering Co. Ltd

Xiaohua Wu

Lianshan Zhang

Baohong Hou

Changyong Yang

Junbo Gong

Qiuxiang Yin

Jingkang Wang

Cheng Liao

Qinqing Gu

Feng Jin

Kaifei Zhao

Shichao Du

Qing Yang

Xiaoxing Huang

Quanren Wang

Dingwei Ye

Haiyan Xi

Shiping Tang

The present disclosure provides the use of an anti-PD-1 antibody in combination with famitinib in the preparation of a drug for treating tumors. In the present technical solution, toxicity is controllable and tolerable. At the same time, the described drug combination effectively reduces adverse reactions to the anti-PD-1 antibody, such as the occurrence of reactive capillary endothelial proliferation.

Use of anti-PD-1 antibody in combination with famitinib in preparation of drug for treating tumors

A method for preparing a new crystalline form of &#x3b3;-aminobutyric acid, including the steps of: S1: preparing a &#x3b3;-aminobutyric acid solution at an initial concentration of 0.5-1.0 g/mL by adding crude &#x3b3;-aminobutyric acid to water; adding an additive to the &#x3b3;-aminobutyric acid solution, raising the temperature to 50-80&#xb0; C., stirring to produce a clear solution; and S2: obtaining a suspension by evaporating water from the product of S1 under reduced pressure and at 50-80&#xb0; C.; obtaining a wet product by filtering the suspension; drying the wet product to obtain the new crystalline form of &#x3b3;-aminobutyric acid. The preparation method of the new crystalline form of &#x3b3;-aminobutyric acid is simple, easy to operate, low in energy consumption, economical and environmentally friendly. It is suitable for large-scale industrial production.

Crystalline form of gamma-aminobutyric acid and preparation method thereof

Growing community of inventors

Jiangsu, China

Xiaohua Wu